<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug</h2>
    <div class="badge">2025-09-08T17:28:09+00:00</div>
    <ul>
      <li>Analysts predict a revenue growth rate of 4.2% per annum over the next few years.</li>
<li>Given the current share price of US$84.71, the analyst consensus price target sits at US$101.75, representing a 20.8% potential upside.</li>
<li>The immediate impact has been a share price boost of 4.98% last month.</li>
<li>Over a five-year period, Merck’s total shareholder return, including share price and dividends, increased by 22.43%.</li>
<li>However, in the last year, the company underperformed compared to the US Pharmaceuticals industry, which returned 11.5%.</li>
<li>Merck recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company&#x27;s 4.98% share price i</li>
<li>We&#x27;ve identified 1 weakness for Merck that you should be aware of.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug\n• Analysts predict a revenue growth rate of 4.2% per annum over the next few years.\n• Given the current share price of US$84.71, the analyst consensus price target sits at US$101.75, representing a 20.8% potential upside.\n• The immediate impact has been a share price boost of 4.98% last month.\n• Over a five-year period, Merck’s total shareholder return, including share price and dividends, increased by 22.43%.\n• However, in the last year, the company underperformed compared to the US Pharmaceuticals industry, which returned 11.5%.\n• Merck recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company&#x27;s 4.98% share price i\n• We&#x27;ve identified 1 weakness for Merck that you should be aware of." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/merck-mrk-gains-breakthrough-therapy-172809106.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>